Listen to a replay of our Q4 2019 Earnings Call

Adaptimmune Announces SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications

Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies

Adaptimmune Appoints Elliot Norry as CMO and Makes Changes to R&D Leadership

You can find new videos about our SPEAR T-cells

Latest News • View all

Adaptimmune on Linkedin linkedin

Adaptimmune on Twitter